An in vivo platform for tumor biomarker assessment

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  Servais, Elliot L ^a   Suzuki, Kei ^a   Colovos, Christos ^a   Rodriguez, Luis ^a   Sima, Camelia ^a   Fleisher, Martin ^a   Rusch, Valerie W ^a   Sadelain, Michel ^a   Adusumilli, Prasad S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; OSTEOPONTIN; PEPTIDE; SOLUBLE MESOTHELIN RELATED PEPTIDE; UNCLASSIFIED DRUG; GLYCOSYLPHOSPHATIDYLINOSITOL ANCHORED PROTEIN; MESOTHELIN; TUMOR MARKER;

ACCURACY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CANCER MODEL; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGING SYSTEM; IN VIVO STUDY; MALE; MALIGNANT MESOTHELIOMA; MOUSE; MULTI MODALITY IMAGING; NONHUMAN; OSTEOPONTIN BLOOD LEVEL; PLEURA MESOTHELIOMA; PROTEIN BLOOD LEVEL; SOLUBLE MESOTHELIN RELATED PEPTIDE BLOOD LEVEL; TREATMENT RESPONSE; VALIDITY; ANIMAL; DIAGNOSTIC IMAGING; MESOTHELIOMA; METHODOLOGY; PLEURA TUMOR; PROCEDURES; STANDARD; VALIDATION STUDY;

ANIMALIA;

ANIMALS; DIAGNOSTIC IMAGING; GPI-LINKED PROTEINS; MESOTHELIOMA; METHODS; MICE; MODELS, ANIMAL; OSTEOPONTIN; PLEURAL NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80055051930     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0026722     Document Type: Article

References (18)

1. Bast RC Jr, Lilja H, Urban N, Rimm DL, Fritsche H, et al. (2005) Translational crossroads for biomarkers. Clin Cancer Res 11: 6103-6108.
2. Makawita S, Diamandis EP, (2010) The bottleneck in the cancer biomarker pipeline and protein quantification through mass spectrometry-based approaches: current strategies for candidate verification. Clin Chem 56: 212-222.
3. Ray M, Kindler HL, (2009) Malignant pleural mesothelioma: an update on biomarkers and treatment. Chest 136: 888-896.
4. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, et al. (2009) Multicenter Phase II Trial of Neoadjuvant Pemetrexed Plus Cisplatin Followed by Extrapleural Pneumonectomy and Radiation for Malignant Pleural Mesothelioma. Journal of Clinical Oncology 27: 3007-3013.
5. Robinson BWS, Musk AW, Lake RA, (2005) Malignant mesothelioma. The Lancet 366: 397-408.
6. Armato SG III, Ogarek JL, Starkey A, Vogelzang NJ, Kindler HL, et al. (2006) Variability in Mesothelioma Tumor Response Classification. Am J Roentgenol 186: 1000-1006.
7. van Klaveren RJ, Aerts JGJV, de Bruin H, Giaccone G, Manegold C, et al. (2004) Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma. Lung Cancer 43: 63-69.
8. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, et al. (2007) Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans. J Nucl Med 48: 1449-1458.
9. Ceresoli GL, Chiti A, Zucali PA, Rodari M, Lutman RF, et al. (2006) Early Response Evaluation in Malignant Pleural Mesothelioma by Positron Emission Tomography With [18F]Fluorodeoxyglucose. Journal of Clinical Oncology 24: 4587-4593.
10. Servais EL, Colovos C, Kachala SS, Adusumilli PS, (2011) Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden. Current protocols in pharmacology/editorial board, SJ Enna Chapter 14: Unit14 21.
11. Adusumilli PS, Eisenberg DP, Stiles BM, Chung S, Chan MK, et al. (2006) Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus. J Thorac Cardiovasc Surg 132: 1179-1188.
12. Adusumilli PS, Stiles BM, Chan MK, Mullerad M, Eisenberg DP, et al. (2006) Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. J Gene Med 8: 603-615.
13. Garbow JR, Wang M, Wang Y, Lubet RA, You M, (2008) Quantitative monitoring of adenocarcinoma development in rodents by magnetic resonance imaging. Clin Cancer Res 14: 1363-1367.
14. Cristaudo A, Foddis R, Vivaldi A, Guglielmi G, Dipalma N, et al. (2007) Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res 13: 5076-5081.
15. Pass HI, Carbone M, (2009) Current status of screening for malignant pleural mesothelioma. Semin Thorac Cardiovasc Surg 21: 97-104.
16. Rai AJ, Flores RM, Mathew A, Gonzalez-Espinoza R, Bott M, et al. (2010) Soluble mesothelin related peptides (SMRP) and osteopontin as protein biomarkers for malignant mesothelioma: analytical validation of ELISA based assays and characterization at mRNA and protein levels. Clin Chem Lab Med 48: 271-278.
17. Brentjens RJ, Santos E, Nikhamin Y, Yeh R, Matsushita M, et al. (2007) Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin Cancer Res 13: 5426-5435.
18. Wheatley-Price P, Yang B, Patsios D, Patel D, Ma C, et al. (2010) Soluble Mesothelin-Related Peptide and Osteopontin As Markers of Response in Malignant Mesothelioma. J Clin Oncol.